3Mourad JJ,des Guetz G,Debhabi H,et al.Blood pressure rise following angiogenesis inhibition by bevacizumab:a crucial role for microcirculation.Ann Oncol,2008,19:927-934.
4Shord SS,Bressler LR,Tiemery LA,et al.Understanding and managing the possible adverse effects associated with bevacizumab.Am J Health Syst Pharm,2009,66:999-1013.
5Reidy DL,Chung KY,Timoney JP,et al.Bevacizumab 5 mg/kg can be infused safely over 10 minutes.J Clin Oncol,2007,25:2691-2695.
6Nalluri SR,Chu D,Keresztes R,et al.Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients:a meta-analysis.JAMA,2008,300:2277-2285.
7Hapani S,Chu D,Wu S.Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab:a meta-analysis.Lancet Oncol,2009,10:559-568.
8Saif MVV,Elfiky A,Salem RR.Gastrointestinal perforation due to bevacizumab in colorectal cancer.Ann Surg Oncol,2007,14:1860-1869.
9Badgwell BD,Camp ER,Feig B,et al.Management of bevacizumab-associated bowel perforation; a case series and review of the literature.Ann Oncol,2008,19:577-582.
